ArticleLancet (London, England)2024
National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
Article in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.JNCI cancer spectrum · 2026Pooled it
- Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis.Frontiers in nutrition · 2026Pooled it
- Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With Overweight/obesity: A Systematic Review and Meta-analysis.Current obesity reports · 2025Pooled it
- The Role of Mobile Apps in Obesity Management: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment ofAnnals of medicine · 2026Trial
- Late-life disability following the action for health in diabetes (Look AHEAD) trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
- The Influence of Ultraprocessed Food Consumption on Energy Intake in Emerging Adulthood: A Controlled Feeding Trial.Obesity (Silver Spring, Md.) · 2026Trial
- Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials.Diabetes, obesity & metabolism · 2025Trial
- Peer Coaching to Support Weight Management in Primary Care: A Cluster Randomized Clinical Trial.JAMA network open · 2025Trial
- Trial
- Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism.Frontiers in endocrinology · 2025Trial
- Stroke in the Young: Incidence, 30-Day Case Fatality Rates, and Risk Factors Over Time in a Population-Based Study.Neurology · 2026Article
- Adipose Tissue Palmitoylation Cycling Mediates Insulin Resistance and Preservation of β-Cell Function in Mice.Diabetes · 2026Article
- Primary Total Knee Arthroplasty Using a Cementless Highly Porous Titanium Tibial Baseplate in Patients Under the Age of 50: An Average 7.6-year Follow-up.Arthroplasty today · 2026Article
- The mediating effects of home environment on the relationship between maternal BMI and childhood obesity: Findings from the ECHO-wide cohort.European journal of pediatrics · 2026Article
- Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World journal of clinical pediatrics · 2026Review
- Obesity and Women's health across the lifespan: A clinical review of life Stage-Specific challenges and treatment considerations.Obesity pillars · 2026Review
- Incidence and etiology of impediments to spinal cord stimulator trial progression.Interventional pain medicine · 2026Article
- The consequences of changes in exercise habits on work engagement and presenteeism: Evidence from an event-study analysis using Japanese longitudinal data.Scandinavian journal of work, environment & health · 2026Article
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes, obesity & metabolism · 2026Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
backgroundOver the past several decades, the overweight and obesity epidemic in the USA has resulted in a significant health and economic burden. Understanding current trends and future trajectories at both national and state levels is crucial for assessing the success of existing interventions and informing future health policy changes. We estimated the prevalence of overweight and obesity from 1990 to 2021 with forecasts to 2050 for children and adolescents (aged 5-24 years) and adults (aged ≥25 years) at the national level. Additionally, we derived state-specific estimates and projections for older adolescents (aged 15-24 years) and adults for all 50 states and Washington, DC.
methodsIn this analysis, self-reported and measured anthropometric data were extracted from 134 unique sources, which included all major national surveillance survey data. Adjustments were made to correct for self-reporting bias. For individuals older than 18 years, overweight was defined as having a BMI of 25 kg/m
findingsIn 2021, an estimated 15·1 million (95% UI 13·5-16·8) children and young adolescents (aged 5-14 years), 21·4 million (20·2-22·6) older adolescents (aged 15-24 years), and 172 million (169-174) adults (aged ≥25 years) had overweight or obesity in the USA. Texas had the highest age-standardised prevalence of overweight or obesity for male adolescents (aged 15-24 years), at 52·4% (47·4-57·6), whereas Mississippi had the highest for female adolescents (aged 15-24 years), at 63·0% (57·0-68·5). Among adults, the prevalence of overweight or obesity was highest in North Dakota for males, estimated at 80·6% (78·5-82·6), and in Mississippi for females at 79·9% (77·8-81·8). The prevalence of obesity has outpaced the increase in overweight over time, especially among adolescents. Between 1990 and 2021, the percentage change in the age-standardised prevalence of obesity increased by 158·4% (123·9-197·4) among male adolescents and 185·9% (139·4-237·1) among female adolescents (15-24 years). For adults, the percentage change in prevalence of obesity was 123·6% (112·4-136·4) in males and 99·9% (88·8-111·1) in females. Forecast results suggest that if past trends and patterns continue, an additional 3·33 million children and young adolescents (aged 5-14 years), 3·41 million older adolescents (aged 15-24 years), and 41·4 million adults (aged ≥25 years) will have overweight or obesity by 2050. By 2050, the total number of children and adolescents with overweight and obesity will reach 43·1 million (37·2-47·4) and the total number of adults with overweight and obesity will reach 213 million (202-221). In 2050, in most states, a projected one in three adolescents (aged 15-24 years) and two in three adults (≥25 years) will have obesity. Although southern states, such as Oklahoma, Mississippi, Alabama, Arkansas, West Virginia, and Kentucky, are forecast to continue to have a high prevalence of obesity, the highest percentage changes from 2021 are projected in states such as Utah for adolescents and Colorado for adults.
interpretationExisting policies have failed to address overweight and obesity. Without major reform, the forecasted trends will be devastating at the individual and population level, and the associated disease burden and economic costs will continue to escalate. Stronger governance is needed to support and implement a multifaceted whole-system approach to disrupt the structural drivers of overweight and obesity at both national and local levels. Although clinical innovations should be leveraged to treat and manage existing obesity equitably, population-level prevention remains central to any intervention strategies, particularly for children and adolescents.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.